Heartland CCOP performs the following activities: 1) enrolls significant numbers of participants to federally-sponsored cancer treatment trials, 2) recruits participants to NCI-sponsored cancer prevention and control studies, 3) participates in cancer screening/early diagnosis clinics and provides education about cancer prevention strategies, 4) educates the public and professional colleagues about cancer research and raises the visibility of NCI trials, 5) participates actively in NCI-sponsored cooperative group life, quality assurance and science. Heartland's two component institutions, Missouri Baptist Medical Center (MBMC) and the Center for Cancer Care and Research (CCCR) each have a long history of high-quality clinical oncology research. The components of that research include: 1) 12 medical oncologists and associated professional staff with clinical trial experience, 2) diligent protection of human subjects according to federal regulations, 3) established, successful participant eligibility screening procedures, and 4) refined protocol and data management procedures. In addition to their accrual and data management efforts, Heartland members have expanded their contributions to the group life of CALGB, NSABP and NCCTG. Heartland continues to expand the existing research program to offer clinical research access to a wide geographic area, as well augmenting the cancer related health of the suburban and rural communities served by the CCOP. The Heartland Research Consortium (Heartland) was developed to reduce cancer incidence, morbidity, and mortality by accelerating the transfer of newly developed cancer prevention and cancer treatment interventions to the populace of St. Louis County and contiguous, medically under-served rural areas in eastern Missouri. In addition to three main offices in West St. Louis County, Heartland maintains four rural outreach clinics. Through these offices and outreach clinics, Heartland provides hematology and oncology services and clinical research access to a total of ten counties in eastern Missouri that would not otherwise be available.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
Kelaghan, Joseph
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Missouri Baptist Medical Center
St. Louis
United States
Zip Code
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Nixon, Andrew B; Pang, Herbert; Starr, Mark D et al. (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res 19:6957-66
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98
Gupta, Pankaj; Mulkey, Flora; Hasserjian, Robert P et al. (2013) A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs 31:1311-20
Ogino, Shuji; Shima, Kaori; Meyerhardt, Jeffrey A et al. (2012) Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 18:890-900
Romanus, Dorothy; Kindler, Hedy L; Archer, Laura et al. (2012) Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage 43:205-17

Showing the most recent 10 out of 26 publications